Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

被引:27
|
作者
Lipton, RB
Pascual, J
Goadsby, PJ
Massiou, H
McCarroll, KA
Vandormael, K
Jiang, KH
Lines, CR
机构
[1] Innovat Med Res Inc, Stamford, CT 06905 USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Univ Hosp Marques de Valdecilla, Santander, Spain
[4] Neurol Inst, London, England
[5] Hop Lariboisiere, F-75475 Paris, France
[6] Merck Res Labs, West Point, PA USA
来源
HEADACHE | 2001年 / 41卷 / 08期
关键词
rizatriptan; sumatriptan; naratriptan; zolmitriptan; 5-HT1B/1D receptor agonists; migraine; nausea; baseline; emergent;
D O I
10.1046/j.1526-4610.2001.01139.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack. Methods.-Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were retrospectively analyzed. Migraine was diagnosed according to International Headache Society criteria. Presence or absence of nausea was recorded at baseline and at 0.5, 1, 1.5, and 2 hours after dosing. The end points analyzed were relief of nausea in those who had it at baseline and emergence of nausea in those who were free of it at baseline. Treatments were compared using odds ratios estimated from logistic regression models at 2 hours, and averaged odds ratios for the first 2 hours posttreatment. Results.-Approximately 60% of patients in each treatment group had nausea at baseline. In those patients with nausea at baseline, significantly more patients treated with rizatriptan 10 mg were free of nausea at 2 hours compared with sumatriptan 100 mg (66% versus 58%, P=.043), sumatriptan 50 mg (68% versus 57%, P=.010), sumatriptan 25 mg (68% versus 59%, P=.017), and naratriptan 2.5 mg (59% versus 45%, P=.014). Averaging over the four posttreatment time points in the first 2 hours, significantly more patients treated with rizatriptan 10 mg were free of nausea compared with sumatriptan 100 mg (P=.004), sumatriptan 50 mg (P=.001), and naratriptan 2.5 mg (P=.015). No significant differences in nausea relief were seen between rizatriptan 10 mg and zolmitriptan 2.5 mg, either at 2 hours (65% versus 61%, P=.210) or over the first 2 hours (P=.781). Rates of treatment-emergent nausea at 2 hours ranged from 11% to 18% with placebo, from 5% to 13% with rizatriptan 10 mg, and from 10% to 20% with other comparator triptans. Conclusions.-Oral rizatriptan 10 mg was more effective than oral sumatriptan and naratriptan at eliminating nausea within 2 hours in patients who had it at baseline. Rates of emergent nausea in patients who were free of it at baseline were low, and no consistent differences were observed between active treatments.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 50 条
  • [21] Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine
    McAllister, Peter
    Berman, Gary
    Kudrow, David
    Smith, Timothy
    Lipton, Richard
    Stock, Elyse
    Stock, David
    Conway, Charles
    Jensen, Christopher
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    NEUROLOGY, 2020, 94 (15)
  • [22] Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
    Shigekazu Kitamura
    Takao Takeshima
    Daishi Yui
    Gabriel Paiva da Silva Lima
    Reija Koukakis
    Cheng Peng
    Ryuji Yoshida
    Yotaro Numachi
    Miki Hasebe
    Neurology and Therapy, 2023, 12 (6) : 1993 - 2006
  • [23] Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
    Kitamura, Shigekazu
    Takeshima, Takao
    Yui, Daishi
    Lima, Gabriel Paiva da Silva
    Koukakis, Reija
    Peng, Cheng
    Yoshida, Ryuji
    Numachi, Yotaro
    Hasebe, Miki
    NEUROLOGY AND THERAPY, 2023, 12 (06) : 1993 - 2006
  • [24] Rimegepant 75mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine
    McAllister, Peter
    Berman, Gary
    Kudrow, David
    Smith, Timothy
    Croop, Robert
    Coric, Vladimir
    Stock, David A.
    Lipton, Richard
    CEPHALALGIA, 2019, 39 : 206 - 207
  • [25] Change in migraine diagnosis after preventive treatment with eptinezumab: Post hoc analysis of the PROMISE studies
    Pozo-Rosich, P.
    Dodick, D. W.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2022, 62 : 134 - 134
  • [26] Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
    Pozo-Rosich, P.
    Dodick, D.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [27] Intravenous Fluids for Acute Migraine. a Post-hoc Analysis of Clinical Trial Data
    Friedman, B.
    Balbin, J.
    HEADACHE, 2015, 55 : 138 - 138
  • [28] Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
    Goadsby, Peter J.
    Dodick, David W.
    Martinez, James M.
    Ferguson, Margaret B.
    Oakes, Tina M.
    Zhang, Qi
    Skljarevski, Vladimir
    Aurora, Sheena K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (08): : 939 - 944
  • [29] Change in Migraine Diagnosis After Preventive Treatment with Eptinezumab: Post Hoc Analysis of the PROMISE Studies
    Cady, Roger
    Pozo-Rosich, Patricia
    Dodick, David
    Ettrup, Anders
    Hirman, Joe
    Asher, Divya
    ANNALS OF NEUROLOGY, 2022, 92 : S40 - S40
  • [30] Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study
    Conaghan, Philip
    Katz, Nathaniel
    Hunter, David
    Hochberg, Marc
    Guermazi, Ali
    Somberg, Kenneth
    Clive, Julia
    Johnson, Mary
    Goel, Niti
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1644 - 1646